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Introduction 
Secukinumab is a human monoclonal antibody 
targeting IL-17A and was the first biologic in this 
class to be FDA-approved for the treatment of 
moderate-to-severe psoriasis. Expected potential 
cutaneous side effects include infection and 
urticaria, though since becoming available 
commercially other cutaneous adverse effects have 
been published. Herein we report a case of a patient 
with a history of atopic dermatitis and psoriasis who 
developed a bullous acral eruption after starting 
secukinumab. 
 
Case Synopsis 
A 44-year-old woman with a history of atopic 
dermatitis and psoriasis on secukinumab presented 
with a new onset of a painful rash on her hands and 
feet. The patient had a longstanding history of 
atopic dermatitis since she was an infant that 
affected her face, trunk, extremities (including her 
hands and feet);  in adulthood she developed a new 
rash on her scalp, trunk, elbows, and knees that was 
diagnosed as psoriasis in 2015. She tried multiple 
treatments for psoriasis, including topical steroids, 
narrow band UVB, adalimumab, and ustekinumab. 
Each therapy initially caused improvement but then 
efficacy would wane. In February 2018, the patient 
was started on secukinumab, receiving the loading 
dose of 300mg at day 0, followed by weekly 300mg 
injections over the subsequent four weeks. In the 
days following her fifth dose, the patient began 
experiencing a painful rash on her palms and soles. 
Other medications she was taking at that time 
included halobetasol ointment, fluocinonide gel, 
and tacrolimus ointment for her psoriasis and atopic 
dermatitis. In addition to these she was taking 
metformin, spironolactone, and norethindrone-
ethinyl estradiol for PCOS and albuterol as needed 
for asthma. These medications were long-standing. 
She had also taken a course of doxycycline for a 
biopsy site infection, which she had tolerated in the 
past without incident. She denied any other new 
medications or supplements in the preceding 
Abstract 
Skin reactions related to secukinumab are 
uncommon. Although the initial phase 3 studies of 
this medication reported infection and urticaria as 
adverse cutaneous events, other cases of unique 
adverse events have since been reported. We are 
presenting a patient who developed an exuberant 
hand and foot reaction after starting secukinumab. 
 
Figure 1: Deep-seated tense vesicles coalescing into bullae on 
soles 
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months and was otherwise feeling well. Physical 
examination was notable for numerous deep-
seated tense vesicles coalescing into bullae on her 
soles (Figure 1) and some on her proximal palms 
(Figure 2). Secukinumab was stopped and the 
patient was started on cyclosporine for possible 
flare of dyshidrotic eczema. Given the patient 
reported excruciating pain and inability to walk, she 
was admitted to the hospital for further care and 
pain control. 
The differential diagnosis at the time of 
presentation included dyshidrotic eczema flare, 
eczema herpeticum, eczema coxsackium, and drug 
reaction. Infectious work up including bacterial and 
fungal tissue cultures, PCR for both HSV 1 and 2, 
Coxsackie A and B, and Parvovirus B19 serologies 
were negative. 
Biopsy of a lesion on the patient’s right foot showed 
spongiotic dermatitis with intra-epidermal vesicle 
formation, as well as a superficial and deep peri-
vascular and interstitial inflammation with many 
eosinophils, most consistent with a hypersensitivity 
reaction (Figures 3A, B). As secukinumab was the 
only new medication exposure started in the 
months prior to this eruption, it was favored to be 
the culprit medication for her reaction. The patient 
was started on cyclosporine 100mg twice daily 
during admission. She improved over the next few 
days while on cyclosporine and corticosteroid wet 
wraps. After two weeks, her dose of cyclosporine 
was decreased to 100mg daily for one month before 
transitioning to methotrexate 10mg weekly. She has 
remained off secukinumab since the eruption 
started, with no new bullous flares in the 
subsequent year. Her psoriasis and atopic dermatitis 
are currently well-controlled with methotrexate 
15mg weekly and topical corticosteroids. 
 
Case Discussion 
Secukinumab is a human monoclonal antibody 
targeting IL-17A and the first biologic in this class to 
be FDA-approved for the treatment of psoriasis in 
2015. IL-17A is expressed on keratinocytes, and 
higher levels of expression have been detected in 
psoriatic lesional skin compared to nonlesional skin 
[1]. Binding of IL-17A leads to expression of 
chemokines and subsequent recruitment of  
 
 
Figure 3: A) Spongiotic dermatitis with intraepidermal vesicle 
formation, H&E, 40×. B) Superficial and deep perivascular and 
interstitial mixed inflammation, H&E, 200×. 
 
Figure 2: Deep-seated tense vesicles on proximal palms 
A
B
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inflammatory cells, resulting in the increased 
epidermal proliferation and skin barrier disruption 
seen in psoriasis [2]. Inhibition of this pathway leads 
to decreased inflammation and rapid improvement 
in skin disease, with a 50% reduction in PASI at 
three weeks; 70% of patients achieve PASI 90 at one 
year [3]. 
The recommended dose of secukinumab for plaque 
psoriasis includes a loading dose of 300mg at weeks 
0, 1, 2, 3, and 4, followed by 300mg every four 
weeks [4]. It is recommended that patients be 
evaluated for tuberculosis (TB) prior to starting 
secukinumab and it should be used with caution in 
patients with chronic or recurrent infections or 
history of inflammatory bowel disease [4]. In 
addition to TB screening, guidelines published by 
the American Academy of Dermatology 
recommend additional screening with IL-17 
inhibitors, including baseline complete blood count 
(CBC), complete metabolic panel (CMP), serologic 
testing for hepatitis B and C, as well as consideration 
of HIV testing if risk factors present [5]. Yearly 
testing for latent TB should be done for patients at 
high risk; otherwise, no further lab monitoring is 
recommended [5]. 
Reported skin related adverse events from phase 3 
trials of secukinumab for psoriasis include oral 
herpes, urticaria, tinea pedis, oral candidiasis, and 
impetigo, though case reports of other cutaneous 
reactions have been reported (Table 1), [4, 6-18]. 
The Naranjo score is a tool that can help determine 
the likelihood that a medication in question is 
responsible for the adverse reaction, which in this 
case is three (Table 2), [19]. However, details 
specific to this patient’s course make the score’s 
interpretation imperfect, with a score of three 
indicating only possible causality. In this case,  
Table 1: Adverse cutaneous events associated with 
secukinumab. Includes reports published through 2018. 
 
Adverse Cutaneous Events Associated With 
Secukinumab 
Event Ref 
Truncal pruritic and psoriasiform eruptions [6-8] 
Lichen planus/lichenoid reaction [9-12] 
Bullous pemphigoid [13] 
Subacute cutaneous lupus erythematosus [14] 
Severe mucositis [15] 
Granuloma annulare [16] 
Dermatophytosis [17] 
Recurrent angular cheilitis [18] 
 
Figure 3: A) Spongiotic dermatitis with intraepidermal vesicle 
formation, H&E, 40×. B) Superficial and deep perivascular and 
interstitial mixed inflammation, H&E, 200×. 
Table 2: Naranjo scale of patient. Her score of 3 suggests a possible causality. Factors specific to this case limit the utility. 
 
Naranjo Scale of Patient [Ref. 19] Yes No Do Not Know Score 
1. Are there previous conclusive reports of the reaction? +1 0 0 0 
2. Did the adverse event appear after the suspected drug was administered? +2 -1 0 +2 
3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? +1 0 0 +1 
4. Did the adverse reaction reappear when the drug was readministered? +2 -1 0 0 
5. Are there alternative causes (other than the drug) that could on their own 
have caused the reaction? 
-1 +2 0 -1 
6. Did the reaction reappear when a placebo was given? -1 +1 0 0 
7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? +1 0 0 0 
8. Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? +1 0 0 0 
9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? +1 0 0 0 
10. Was the adverse event confirmed by any objective evidence? +1 0 0 +1 
Total Score: 3 
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secukinumab was only made publicly available in 
2015 and so reports of reactions are limited. As the 
patient’s reaction was severe and led to hospital 
admission, rechallenge of the medication was not 
done, particularly since multiple alternative 
treatments exist for psoriasis. No assay is available 
commercially to detect the medication in the blood 
and the toxicity level is not known. As the patient 
was completing her loading dose at the start of the 
reaction, we are unable to assess changes in the 
reaction with dose changes. She had never used this 
medication or other IL-17 inhibitors before, so 
previous exposure cannot be assessed. For these 
reasons, the score was not able to reach a definite 
likelihood score of 9. Although our patient had 
completed a one-week course of doxycycline 
100mg twice daily in the two weeks prior to hospital 
admission, she had been on this medication before 
without issue. Doxycycline is also widely used with 
the most common skin-related adverse event being  
photosensitivity [20]. Therefore, given the timing of 
the administration of secukinumab weekly in the 5 
weeks prior to this eruption, improvement with 
cessation of the medication, and a biopsy consistent 
with a hypersensitivity reaction, the most likely 
cause of reaction secondary to secukinumab is 
favored. 
 
Conclusion 
To our knowledge, this is the first reported case of a 
bullous acral eruption from secukinumab. As 
secukinumab may be started in patients with pre-
existing palmar and plantar skin disease, we would 
like to spread awareness of this potential drug 
reaction that may occur so that the medication can 
be stopped in a timely manner. 
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